KALA BIO Q1 net loss $11.8M; Phase 2b CHASE trial enrolling, topline data by year-end 2024

KALA BIO, Inc.

2025-Q1 EPS reported -$4.20 vs consensus -$103.53 ▲ beat (+95.9%)

Phase 2b CHASE trial of KPI-012 for PCED enrolling; topline data expected by year-end 2024.
Cash and equivalents $48.5M as of March 31, 2024; with CIRM award, funds operations into Q3 2025.
Q1 2024 net loss $11.8M ($4.20/share) vs $14.5M ($6.99/share) in Q1 2023; operating loss $11.9M.
R&D expenses rose to $6.4M from $4.0M year-over-year, driven by KPI-012 development.
Gross proceeds of $8.6M from March 2024 private placement partially offset cash used in ops.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KALA BIO, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a general business update.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-008133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.